倍轻松实控人再遭立案

Core Viewpoint - The company Beike (688793.SH) is under investigation by the China Securities Regulatory Commission (CSRC) for market manipulation, involving its actual controller and chairman, Ma Xuejun, who has been investigated twice in a short period for various financial misconducts [1][2]. Group 1: Company Background - Beike was established in 2001 and went public on the Sci-Tech Innovation Board in July 2021, focusing on the design, research, development, production, sales, and service of smart portable health hardware, including products like neck and eye massagers [1]. - Ma Xuejun has been the main operator since the company's inception, holding a direct stake of 37.51% and controlling a total of 49.38% of the shares, giving him absolute control over the company [1]. Group 2: Financial Misconduct - Ma Xuejun has been involved in various financial misconducts, including the misappropriation of company funds totaling 16.69 million yuan through employee loans, transferring 54 million yuan via related companies, and prepaying suppliers, with a total of 85.93 million yuan misappropriated in 2024 alone [2]. - The company has also failed to disclose 30 million yuan in illegal guarantees, raising further concerns about its governance [2]. Group 3: Financial Performance - In 2024, Beike reported revenues of 1.085 billion yuan and a net profit of only 10.25 million yuan. By the third quarter of 2025, the company's total assets were 676 million yuan, liabilities were 398 million yuan, and shareholders' equity was reduced to 278 million yuan, with a negative cash flow from operating activities of 28.1 million yuan [3]. - As of February 6, 2026, the company's stock price was 22.71 yuan per share, reflecting a decline of approximately 81.5% from its peak market value, with a total market capitalization of 1.952 billion yuan [3]. Group 4: Regulatory Response - The company stated that the investigation pertains to Ma Xuejun personally and is not expected to significantly impact its daily operations, with Ma continuing to fulfill his duties and the company pledging to cooperate with the regulatory investigation [3].